29910725|t|The Role of Fluoxetine in Activating Wnt/beta-Catenin Signaling and Repressing beta-Amyloid Production in an Alzheimer Mouse Model.
29910725|a|Fluoxetine (FLX) is one of the selective serotonin reuptake inhibitors (SSRIs) antidepressants, which could be used to relieve depression and anxiety among AD patients. This study was designed to search for new mechanisms by which fluoxetine could activate Wnt/beta-catenin signaling pathway and reduce amyloidosis in AD brain. Fluoxetine was administered via intragastric injection to APP/tau/PS1 mouse model of Alzheimer's disease (3xTg-AD) mice for 4 months. In the hippocampus of AD mouse model, there could be observed neuronal apoptosis, as well as an increase in Abeta (amyloid-beta) production. Moreover, there is a strong association between down-regulation of Wnt/beta-catenin signaling and the alteration of AD pathology. The activity of protein phosphatases of type 2A (PP2A) could be significantly enhanced by the treatment of fluoxetine. The activation of PP2A, caused by fluoxetine, could then play a positive role in raising the level of active beta-catenin, and deliver a negative impact in GSK3beta activity in the hippocampal tissue. Both the changes mentioned above would lead to the activation of Wnt/beta-catenin signaling. Meanwhile, fluoxetine treatment would reduce APP cleavage and Abeta generation. It could also prevent apoptosis in 3xTg-AD primary neuronal cell, and have protective effects on neuron synapse. These findings imply that Wnt/beta-catenin signaling could be a potential target outcome for AD prevention, and fluoxetine has the potential to be a promising drug in both AD prevention and treatment.
29910725	12	22	Fluoxetine	Chemical	MESH:D005473
29910725	41	53	beta-Catenin	Gene	12387
29910725	109	118	Alzheimer	Disease	MESH:D000544
29910725	119	124	Mouse	Species	10090
29910725	132	142	Fluoxetine	Chemical	MESH:D005473
29910725	144	147	FLX	Chemical	MESH:D005473
29910725	259	269	depression	Disease	MESH:D003866
29910725	274	281	anxiety	Disease	MESH:D001007
29910725	288	290	AD	Disease	MESH:D000544
29910725	291	299	patients	Species	9606
29910725	363	373	fluoxetine	Chemical	MESH:D005473
29910725	393	405	beta-catenin	Gene	12387
29910725	435	446	amyloidosis	Disease	MESH:D000686
29910725	450	452	AD	Disease	MESH:D000544
29910725	460	470	Fluoxetine	Chemical	MESH:D005473
29910725	526	529	PS1	Gene	19164
29910725	530	535	mouse	Species	10090
29910725	545	564	Alzheimer's disease	Disease	MESH:D000544
29910725	566	573	3xTg-AD	CellLine	CVCL:A2NA
29910725	575	579	mice	Species	10090
29910725	616	618	AD	Disease	MESH:D000544
29910725	619	624	mouse	Species	10090
29910725	656	674	neuronal apoptosis	Disease	MESH:D065703
29910725	702	707	Abeta	Gene	11820
29910725	806	818	beta-catenin	Gene	12387
29910725	851	853	AD	Disease	MESH:D000544
29910725	914	918	PP2A	Gene	51792
29910725	972	982	fluoxetine	Chemical	MESH:D005473
29910725	1002	1006	PP2A	Gene	51792
29910725	1018	1028	fluoxetine	Chemical	MESH:D005473
29910725	1093	1105	beta-catenin	Gene	12387
29910725	1140	1148	GSK3beta	Gene	56637
29910725	1254	1266	beta-catenin	Gene	12387
29910725	1289	1299	fluoxetine	Chemical	MESH:D005473
29910725	1340	1345	Abeta	Gene	11820
29910725	1393	1400	3xTg-AD	CellLine	CVCL:A2NA
29910725	1501	1513	beta-catenin	Gene	12387
29910725	1564	1566	AD	Disease	MESH:D000544
29910725	1583	1593	fluoxetine	Chemical	MESH:D005473
29910725	1643	1645	AD	Disease	MESH:D000544
29910725	Association	12387	51792
29910725	Negative_Correlation	MESH:D005473	11820
29910725	Positive_Correlation	MESH:D000544	11820
29910725	Association	MESH:D000544	12387
29910725	Negative_Correlation	MESH:D005473	56637
29910725	Positive_Correlation	MESH:D005473	12387
29910725	Negative_Correlation	MESH:D005473	MESH:D000544
29910725	Negative_Correlation	51792	56637
29910725	Positive_Correlation	MESH:D005473	51792
29910725	Negative_Correlation	MESH:D005473	MESH:D003866
29910725	Negative_Correlation	MESH:D005473	MESH:D001007
29910725	Negative_Correlation	MESH:D005473	MESH:D000686

